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Interaction of Testosterone-Based Compounds
with Dodecyl Sulphate Monolayers at the Air-Water
Interface†
Daniel T. Allen,a Nikou Damestani,a Yussif Saaka, b M. Jayne Lawrence c and Christian
D. Lorenz ∗a
A series of atomistic molecular dynamics simulations investigating the interactions between
three different testosterone-based compounds (testosterone (T), testosterone propionate (TP)
and testosterone enanthate (TE)) and sodium dodecyl sulphate (SDS) and ammonium dodecyl
sulphate (ADS) monolayers, which vary only in the sodium or ammonium counterions used to
neutralise the sulphate headgroup. These simulations were used to investigate how the struc-
tural and interfacial properties of the monolayer was affected by changing the number of drug
molecules present per monolayer, and the chemical nature of the surfactant counterions and the
testosterone-based compounds. Our results show that the structure of the interfacial water layer
is affected by the change of the counterion but not the chemistry of the drug molecules. As a
result of the difference in their chemical structure, the T, TP and TE drug molecules take different
locations and orientations within the monolayers. Finally, we observed that the hydration of the
drug molecules encapsulated within the ADS monolayers is significantly less than when they are
encapsulated within the SDS monolayers. Understanding the role that the counterion and the
chemistry of the drug molecules in these systems provides us with a detailed description of the
interactions that cause ADS micelles to encapsulate significantly less drug molecules than SDS
micelles, which we have recently observed experimentally.
1 Introduction
The unique chemical structure of surfactants enables them to
form a variety of self-assembled structures including monolayers
at the air-water interface and micelles, vesicles and bilayers in so-
lution. The ability to form these complex nanostructures allows
surfactants to be used in the production of novel pharmaceutical,
food and personal care products, material recovery processes, and
environmental remediation1–15. In all of these applications, the
hydrophobic interior of the aggregate structures can be used to
solubilise other slightly soluble nonpolar substances.
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While surfactants are widely applied in the formulation of
drug delivery vehicles, the understanding of how the molecular
structures of surfactants and drug compounds affect the drug-
surfactant interactions and therefore the solubilisation of the
drugs into aggregates of the surfactant is still quite limited. In
general, it is understood that the solubilisation of a drug depends
on the hydrophobic interactions between the drug and surfac-
tant molecules, while hydrophilic and electrostatic interactions
of the drug molecules will affect their location within the ag-
gregates16,17. While this understanding of the basic interactions
that govern the behaviour of surfactant-based drug formulations
is useful, it is not enough to attempt to optimise the composition
of a formulation to maximise the encapsulation and stability of an
aggregate. Therefore there is a significant interest in generating
a more detailed understanding on how the surfactant-drug inter-
actions and the interactions of the surfactant and drug with the
solvent phase affect the solubilisation and structure of the micelle,
which in turn can be used to optimise its drug delivery properties.
Molecular dynamics (MD) simulations are a powerful tool that
have the capability to provide detailed information regarding
the interactions which govern the encapsulation process of small
molecules into self-assembled aggregates of surfactants. As a re-
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sult there have been used in several investigations of the solu-
bilisation of small molecules in surfactant micelles1,18–21,21–25.
Meanwhile, there has been a wealth of scientific research using
MD simulations to gain a similar understanding of the molecular-
scale interactions that govern the interfacial properties of the sur-
factants and the self-assembled structures that they form at the
air/water interface26–38. However, very little has been done with
simulations investigating the interactions of drug molecules with
surfactant monolayers, and the research that has been done pri-
marily focusses on the interaction of drug molecules with lipid
monolayers39–43. Experimentally, the best way of gaining infor-
mation on the amount of drug incorporated into a monolayer and
the resulting location of the drug within a monolayer is specular
neutron reflectivity (SNR). However, as is the case with MD simu-
lations, very little research has been reported on the interactions
of small molecules and surfactant monolayers. The experimental
investigations that have been reported were focussed on oil44,45
and fragrance46,47 molecules. Only recently have we reported
an interdisciplinary investigation of a drug molecule with a SDS
monolayer48.
In this study, we used classical MD simulations to investi-
gate the interactions between three different testosterone-based
compounds (testosterone (T), testosterone propionate (TP) and
testosterone enanthate (TE)) and sodium dodecyl sulphate (SDS)
and ammonium dodecyl sulphate (ADS) surfactants, which vary
only in the sodium or ammonium counterions used to neutralise
the sulphate headgroup (see Fig. 1 for molecular structures).
The position, orientation and hydration of the three testosterone-
based compounds were investigated within monolayers of each
surfactant. As surfactant monolayers and micelles are in ther-
modynamic equilibrium with one another and both exist in ex-
perimental systems when the concentration of surfactants within
the system is above the critical micelle concentration (cmc), then
the structural and interfacial properties of the monolayers stud-
ied here will be related to those in a micelle. The results of
this investigation provide a detailed understanding of the inter-
actions that result in the reduced encapsulation of testosterone-
based compounds in ADS micelles as compared to their encapsu-
lation in SDS micelles49. Additionally, these results provide an
insight into how modifying the chemistry of drug molecules and
the molecules used to encapsulate them can affect the positioning
of the molecules within the drug delivery vehicle.
2 Model and Methodology
2.1 Simulated systems
All-atom MD simulations were used to investigate the structural
and interfacial properties of ADS and SDS surfactant monolay-
ers at the air/water interface with different counterions. Each
of these monolayer systems were comprised of two monolayer
leaflets separated by a 60 Å thick water slab, which ensured that
the electrostatic interactions from one monolayer were not felt by
the other monolayer. The resulting water slab consists of 9600
water molecules with a density of 1 g/ml.
The initial structures of the DS− monolayers, each consisting of
100 DS− molecules, were built using the Packmol software pack-
(a) (b)
(c) (d)
Fig. 1 The chemical structures of: a) DS− with Na+ and NH+4 counte-
rions, b) T, c) TP, d) TE. In these figures, the colours cyan, white, red,
yellow, green and blue are used to represent the elements: carbon, hy-
drogen, oxygen, sulphur, sodium and nitrogen respectively.
(a) (b)
Fig. 2 Initial configurations of (a) the SDS monolayer system and (b)
the SDS monolayer system with testosterone molecules. The colours
cyan, white, red, yellow and green are used to represent the elements:
carbon, hydrogen, oxygen, sulphur and sodium respectively. In (b), the
testosterone molecules are visible in the vacuum regions both above and
below the respective monolayer leaflets.
age50 and were neutralised by the addition of 100 Na+/NH+4
counterions for the SDS/ADS systems per leaflet, which were
placed near the headgroup regions of the DS− molecules. The
simulation box was built with x− and y− dimensions of 69.28 Å
each such that the area per surfactant was ∼ 48 Å2. The area per
surfactant used in the DS− monolayer simulations is in agreement
with the experimentally determined value for SDS monolayers51
and was used for all reported monolayers so that the system prop-
erties can be fairly compared. Periodic boundary conditions were
applied in all dimensions, with the z− dimension of the simula-
tion box set to 200 Å to ensure that the monolayers do not inter-
act with one another through the periodic boundary in the z-axis.
The centre of mass of each system was constrained to be at the
position z = 0 throughout the simulation to make the analysis of
the simulation as easy as possible. The initial configuration for
the SDS monolayer system is shown in Figure 2a, illustrating the
monolayer geometry.
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The testosterone-based compounds (testosterone (T), testos-
terone propionate (TP) and testosterone enanthate (TE)), whose
chemical structures are shown in Figure 1, were introduced after
the ADS/SDS monolayers were thoroughly equilibrated. The drug
molecules were initially placed randomly in the vacuum regions
above and below the top and bottom monolayer leaflets respec-
tively in each system, within 5-10 Å of the hydrocarbon tails and
oriented such that they were perpendicular to the z-axis, as shown
in Figure 2b. The placement of the drug molecules in these re-
gions mimicked the placement of the drugs in the experiments in
which n-hexane was used to deliver the drugs onto the hydrocar-
bon tails of the monolayers. In each case, each drug/monolayer
combination was studied with three different numbers of drug
molecules per monolayer present: (a) a single drug per mono-
layer, (b) a number of drugs per lipid that is representative of
what is found in the micelles from solubilisation experiments and
the fitting of neutron scattering experiments of the same sys-
tems49, and (c) twice the number of drugs per surfactant found
in the micelles experimentally.
2.2 Simulation protocol
The same simulation protocol was used for each simulation to
study the various systems presented in this manuscript.
First, an energy minimisation was performed on each of mono-
layer systems using 100 000 steps as the maximum number of
force/energy evaluations. Then the minimum energy state was
simulated in the NVT ensemble for 10 ns for thermalisation. The
ADS and SDS monolayer systems were simulated a further 50 ns
in the NVT ensemble to equilibrate the monolayers before the
drug molecules were added. Then the final configuration from
these equilibration simulations were used to build the systems
with the different drug molecules. The drug molecules were
placed within 5-10 Å of the terminal methyl groups of the hy-
drocarbon tails of the DS− surfactants, and the drug molecules
were oriented with their primary axis perpendicular to the z-axis.
Finally, these various systems were simulated for a further 50 ns
using the NVT ensemble in order to investigate the interations
between the testosterone-based compound and the DS− mono-
layers.
All of the simulations presented in this manuscript were per-
formed at T = 300 K using the LAMMPS simulation package52
with the CHARMM force field53,54 for the description of both
inter- and intra-molecular interactions of the DS− molecules,
the various counterions and also the testosterone-based com-
pounds55,56. The TIP3P water model57, modified for the
CHARMM forcefield58, was used to describe interactions involv-
ing water. This combination of forcefields has previously been
shown to give a good description of SDS micelles and DS− mono-
layers1,26,59,60.
The van der Waals interactions were cut-off at 10 Å whilst
the electrostatic interactions were cut-off at 12 Å. The PPPM
method61 was used to compute long-range Coulombic interac-
tions. The equilibration and production runs for all monolayer
simulations utilised the Nose-Hoover thermostat62 to fix the sys-
tem temperature. A timestep of 2 fs was used in all simula-
tions to ensure stable integration of Newton’s equations of motion
with the velocity Verlet algorithm whilst all hydrogen-containing
bonds were constrained using the SHAKE algorithm63. All of the
measurements reported in this manuscript were conducted using
the last 10 ns of the production simulations, during which the
position of the drug molecules within the monolayers and the
orientation of the surfactant molecules was observed to not be
changing significantly.
2.3 Analysis of simulation trajectories
2.3.1 Constructing an intrinsic surface for a surfactant
monolayer
Developing a description of the interfacial behaviour and struc-
ture of surfactant aggregates is crucial to understanding their
function for many different processes. Physical properties such
as size, geometry/shape, hydrophobicity and roughness all have
an affect on the observed behaviour of aggregates and are largely
influenced by the surface properties. It is therefore of vital impor-
tance that a thorough and careful treatment of the interfaces of
these structures be incorporated into analysis.
For a system comprising of two distinct phases, the intrinsic
surface, denoted by ξ (R) = ξ (x,y), is defined as the location in
which one phase comes in contact with the other. In general, the
intrinsic surface is constructed from a finite number of anchor
points: atoms which are deemed to be at the interfacial region.
For DS− monolayers, the sulphur atoms in the DS− head groups
are generally used as the anchor points, as they will generally be
found near the monolayer/water interface.
There are a number of different ways to construct the intrinsic
surface for liquid interfaces reported in the literature. For com-
putational efficiency, the algorithm proposed by Berkowitz et al64
was employed in this manuscript to determine the intrinsic sur-
face of the DS− monolayers, as it was employed previously to
investigate the interaction of various counterions with DS− sur-
factants26. In essence, this method is performed by projecting
the location of a particle of interest and the anchor points used
to define the interface onto the x-y plane. Next, the closest an-
chor point to the particle of interest within this projected two-
dimensional representation is established. Finally, the location
of the intrinsic surface for the particle of interest is assigned the
value of the z-coordinate of the closest anchor point.
2.3.2 Determination of the intrinsic density
In the DS− monolayer systems, the intrinsic density is used to de-
scribe the average density of different atomic species as a function
of their distance away from the intrinsic surface. The intrinsic
density provides a description of the interfacial structure of the
various atomic components in the system such as counterions,
solvent and drug molecules. The intrinsic density is particularly
useful for describing the structure of water molecules in the vicin-
ity of the interface, which is known to strongly impact the ability
of solutes to penetrate through the monolayer surface.
The intrinsic density of a given atomic species is defined math-
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ematically as:
ρ˜(z) =
〈
1
A0
N
∑
i=1
δ (z− zi+ξ (Ri))
〉
(1)
where the summation indexed by i runs over all N particles of
a given atomic species, ξ (Ri) represents the intrinsic surface for
a given configuration, Ri = (xi,yi) is the location of particle i in
the x-y plane for a given configuration and A0 is the cross sec-
tional area of the interface. The z-coordinate of the ith particle
is denoted by zi and z represents the vertical distance from the
DS−/water interface to particle i where values of z > 0 and z < 0
represent locations within the water slab and towards the vacuum
region respectively.
2.3.3 Measurement of monolayer structural properties
A detailed description of the monolayer structure has been
achieved by calculating different quantities to study how mono-
layer structure changes with the addition of testosterone-based
compounds. In the following paragraphs, these quantities are ex-
plained in detail.
The thickness of the DS− monolayers provide insight into how
the surfactants arrange and orient themselves within the mono-
layer. In this manuscript, the thickness of the hydrocarbon tail
dtail and the head group dhead of the surfactants have been de-
termined. The thickness of the hydrocarbon tail was determined
by taking the difference between maximum and minimum val-
ues of the z-coordinates of the carbons in the tails of each DS−
molecule. Then the value of dhead is determined by averaging
over all molecules in all configurations.
Meanwhile, the instantaneous thickness of the headgroup region
of the DS− monolayer is calculated in a similar manner as the tail
thickness and can be used to monitor how the head group region
is affected as the composition of drug molecules changes. The
thickness of a headgroup in a given DS− molecule is determined
by first establishing the maximum and minimum z-coordinates
of the four oxygen atoms in the headgroup, and then taking the
difference between the maximum and minimum of these z-values.
Then to find the thickness of the headgroup region of a monolayer
dhead, this distance is averaged over all DS− molecules in every
snapshot.
The monolayer interfacial roughness can strongly influence the
ability of solutes to penetrate through the monolayer surface.
The interfacial roughness is described by the value of the root-
mean-squared deviation (RMSD) for the difference between the z-
coordinate of a sulphur atom in the DS− headgroup and the mean
value of the z-coordinates of all sulphur atoms present in a mono-
layer within a given configuration of the trajectory: |zi− zavg|.
The structure of the DS− molecules within the monolayers
can also be described via different geometric measures of the
molecules. For example, the surfactant chain tilt angle, θt, is de-
fined as the angle between the vector formed between the C1
atom (the carbon nearest the head group) and the C12 atom (the
terminal carbon of the hydrocarbon chain) and a unit vector in
the z-direction. When this angle is zero, the hydrocarbon tail is
parallel to the z-axis and when this angle is 90◦, the DS− molecule
is lying in the x-y plane. Additionally, the surfactant headgroup tilt
angle, θh, was also investigated for all of the monolayer systems
and is defined as the angle between the vector formed between
S (the sulphur atom in the DS− headgroup) and C1 atoms, and
the vector formed between C1 and C12 atoms. When this angle is
zero, the entire molecule is aligned linearly and when this angle is
90◦ the headgroup is oriented such that it is perpendicular to the
DS− hydrocarbon chain. In both cases, these angles are averaged
every molecule in a configuration and over all configurations that
were analysed.
The surface tension of the surfactant monolayers loaded with
drug molecules is calculated direclty for each system. The mono-
layer surface tension (γm) is determined from the difference be-
tween the normal (PN) and lateral (PL) pressures as shown:
γm =
〈
(PN −PL)× (Lz/2)
〉
, (2)
where Lz is the box size in the direction normal to the monolayer
interfaces. As the normal is oriented along the z-axis in our sys-
tems, the lateral pressure PL is the average of the pressure in the
x- (Pxx) and y-directions (Pyy): PL = (Pxx+Pyy)/2. The values of γm
reported here are calculated and then averaged over 10 ns of the
production simulation.
2.3.4 Position and Orientation of Testosterone Compounds
The preferred position and orientation of drug molecules within
surfactant aggregates has profound implications on the nature
of their encapsulation properties. These may be affected by the
chemical nature of the drug and also the physical characteristics
of the surfactant species itself, such as the choice of counterion
and hydrophobic tail length. The orientation of drug molecules is
described by the cosine of the angle formed between the vector
pointing from the O2 atom to the O1 atom (see Figure 1) in the
drug molecule and the unit vector: (0,0,1) or (0,0,-1) for drug
molecules in the top or bottom monolayer leaflets respectively.
When cos(θ) is equal to -1, the entire drug molecule is aligned
parallel to the z-axis with the O2 atom nearest the vacuum region
and the O1 atom nearest the water slab, when cos(θ) is equal to
0 the drug molecule is oriented in the x-y plane and when cos(θ)
is equal to 1, the drug molecule is again aligned parallel to the
z-axis but with the O1 atom nearest the vacuum region and the
O2 atom nearest the water slab.
The location of a drug molecule is used to determine how deep
a drug molecule is inserted into the monolayer and is defined
as the midpoint of the vector connecting the O1 and O2 atoms
(vO1,O2). In this case, the orientation distributions are calculated
as a function of the distance that the drug molecule is away from
the intrinsic surface of the monolayer into the hydrocarbon tail
region. The space amongst the surfactant monolayers has been
divided into four distinct regions: Headgroup, C1−4, C5−8 and
C9−12. These regions are determined by first determining the sur-
factant molecule which is closest in the x-y plane. Then the z-
coordinates of the atoms in the surfactant molecule were used to
define these four regions, and the z-coordinate of vO1,O2 was used
to identify which region the drug molecule resided in. It should
be noted that the size of these regions will vary as the tilt angle of
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the individual surfactant chains vary, but this method is consistent
with identifying an intrinsic surface at the four different levels
and mapping it out across the monolayers and using these sur-
faces as criteria for identifying the location of the drug molecule
as is done for the solvent phase in reference to the monolayer
surface.
3 Results
In this section, the results of the previously described analyses are
presented for the SDS and ADS monolayers with each of the three
different testosterone derivatives.
3.1 Monolayer intrinsic density
(a) SDS-T (b) ADS-T
(c) SDS-TP (d) ADS-TP
(e) SDS-TE (f) ADS-TE
Fig. 3 Intrinsic density profiles for the monolayer simulations. The
colours green, blue and magenta are used to depict the density of DS−
elements: oxygen, carbon, and sodium/nitrogen in the counterions re-
spectively. The colours blue and black depict the density of oxygen atoms
in water and carbon atoms in the testosterone-based molecules respec-
tively. (Note: the errors on these measurements are smaller than the size
of the symbols used to represent them.)
Intrinsic density profiles, shown in Figure 3, provide a de-
tailed characterisation of the interfacial water structure and the
location of testosterone-based compounds within the monolay-
ers. One significant distinction between these plots for SDS and
ADS monolayers is the density profiles of oxygen atoms in wa-
ter molecules, OW, as shown by the blue curves in Figure 3. At
smaller values of z, corresponding to the monolayer interfacial re-
gion, the SDS monolayers exhibit two distinct density peaks. The
largest peak is situated at z= 3.5 Å whilst the smaller peak is lo-
cated at z= 6 Å which indicates that there are two interfacial wa-
ter layers near the SDS headgroups. For the ADS monolayers, the
structure of water molecules in the interfacial region is quite dif-
ferent. Rather than exhibiting peaks, the density of OW atoms re-
mains constant at the bulk value and it begins to decrease mono-
tonically from the headgroup region for some distance inside the
monolayer hydrocarbon tail region (z < 0). Therefore, the wa-
ter is less ordered at the interface of the ADS monolayers than
the SDS monolayers, which is consistent with what we observed
when studying DS− monolayers with different counterions in the
absence of drug molecules26. Therefore, the effect of changing
the type and the number of drug molecule present within the
monolayers has a negligible effect on the interfacial water den-
sity, whereas changing the counterion species has a large effect.
Within the monolayer hydrocarbon tail region, z< 0, the water
density decays and eventually reaches zero in all systems. For the
SDS monolayers with 1 drug molecule present, there is a small
peak in the density of the OW atoms located at approximately
z = −3 Å, which is where the hydrocarbon tails merge with the
SDS head group (as z=−3 Å is the location where the density of
the oxygens in the SDS headgroup and the density of the carbons
in the SDS tails overlap). For the SDS systems, this water density
peak within the monolayer becomes less prominent as more drug
molecules are present, thus the addition of drug molecules results
in the expulsion of water from this region of the monolayer. Ad-
ditionally, none of the ADS monolayers have appreciable density
peaks for OW atoms within the monolayers.
The amount of water within each monolayer nH2O was calcu-
lated for all systems by integrating the intrinsic density of OW
atoms over z from −∞→ 0, which therefore provides a measure
of the average number of water molecules contained within the
monolayer interior per unit area. The values for nH2O are shown
in Table 1 & 2 for the SDS and ADS monolayers, respectively.
These values reveal that as the number of drug molecules present
per monolayer increases, the value of nH2O decreases for all of
the systems. As the monolayers become more densely packed by
the addition of drug molecules, water is forced into the bulk wa-
ter region where it can form more favourable interactions than in
the monolayer tail region. The ADS monolayers contain signifi-
cantly less water within their tail regions. For example, the val-
ues of nH2O for SDS-T-1 and ADS-T-1 are 0.16 Å
−2 and 0.10 Å−2
respectively. Similarly, comparing SDS-TP-1, SDS-TE-1 and ADS-
TP-1, ADS-TE-1 reveals nH2O values of 0.15 Å
−2 and 0.10 Å−2 for
SDS and ADS respectively. Therefore by changing the counteri-
ons from sodium to ammonium, the water contained within the
monolayer decreases by 33% which is significant. The amount of
water contained within the interior of surfactant aggregates could
have a profound effect on their resulting solubilising ability49.
The intrinsic density profiles of the sodium and ammonium
counterions are shown by the magenta curves in Figure 3 and
exhibit a single broad density peak around the monolayer inter-
face (−5 < z < 5) in all systems. Therefore, the counterions are
situated in the vicinity of the interfacial region, which is also con-
firmed from visual inspection of the simulation trajectories.
The green curves in Figure 3 show the intrinsic density of oxy-
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gen atoms in DS− molecules, ODS, for all of the monolayers.
For the SDS monolayers with a small number of drug molecules
present, these distributions exhibit a peak located at z= 0 Å, and
a shelf located just beneath the monolayer surface at z ∼ −1 Å.
As the number of drug molecules is increased, this density dis-
tribution splits into two distinct peaks, the largest of which cor-
responds to the three ionic oxygen atoms in the surfactant head
group, whereas the second smaller peak arises due to the oxy-
gen atom which is bonded to the C1 and S atoms in the surfac-
tant. As more drug molecules are added to the monolayer, the
dynamics of the head groups becomes restricted which results in
the increased prominence of the two density peaks of ODS atoms.
In the ADS monolayers, the ODS intrinsic density profiles show
even sharper peaks than those in SDS; however unlike the SDS
monolayers, these peaks are unchanged by the addition of more
drug molecules. The counterion species is the predominant fac-
tor in determining the structure of the monolayer interface, as
opposed to the type or number of the testosterone-based com-
pounds present.
The intrinsic density profiles of carbon atoms in DS− molecules,
CDS, are shown by the cyan curves in Figure 3 and represent the
surfactant hydrocarbon chains. These density profiles are non-
zero in the region from the monolayer interface (z ∼ 0) to ap-
proximately z = −15 Å for all of the SDS and ADS monolayer
simulations. There is no significant change in the CDS intrinsic
density profiles as the counterion species is changed, however as
the number of drug molecules present in the monolayer increases,
the CDS density profile flattens out to some extent. This effect is
most clearly illustrated in the SDS-TE simulations as the number
of TE is increased from 1 to 34, but can be seen in all of the
different systems.
The intrinsic density of the carbon atoms (CT, CTP and CTE for
T, TP and TE respectively) in the drug molecules is used to deter-
mine their location in the monolayers. Figure 3 shows the intrin-
sic density profiles of the carbon atoms in the testosterone-based
compounds. The black curves show that these molecules are lo-
cated amid the DS− hydrocarbon tails and not at the interface. As
more drug molecules are added, the density peaks remain around
approximately the same value of z ∼ −5 Å whilst the magnitude
of the peaks increase slightly as the additional drug molecules ac-
cumulate in the same region of the monolayer. In a recent study,
we have shown with both neutron reflectivity and MD simula-
tions that TE resides in the same region of the monolayers when
the area per surfactant is changed, and only when the concentra-
tion of TE becomes super saturated is there a population of drug
molecules which are expelled into the vacuum region outside of
the monolayers48.
3.2 Orientation and position of testosterone-based
compounds in monolayers
The intrinsic density plots reveal that the testosterone-based com-
pounds are generally situated within the DS− hydrocarbon tail
region. However they do not contain any information about the
orientation of these molecules at different positions within the
monolayer, nor do they provide any specific detail about the drug
location in reference to the surfactant molecules. The intrinsic
drug orientation was described earlier in Section 2.3.4. Figure 4
shows the drug orientation distributions as a function of distance
from the intrinsic surface for the monolayer simulations. One
prominent difference between these distributions is that T sam-
ples a wider range of orientations compared to TP and TE, as
shown by the relatively flat distributions across cos(θ) in Fig-
ures 4a and 4b. Additionally, the T molecules occupy both the
C1−4 and C5−8 regions in the monolayers with just a single T
molecule. However, as more T molecules are added to the mono-
layers, the C5−8 region becomes more densely populated and the
drug molecules also tend to reorient themselves such that they
are perpendicular to the monolayer/water interface. In doing so,
the majority of the T molecules orient with their O1 and O2 atoms
are nearest the water and the vacuum region, respectively. While
there is a smaller popultion of T molecules which are oriented
(cos(θ) ∼ 0.9) with their O2 atoms nearest the water and the O1
nearest the vacuum region.
(a) SDS-T (b) ADS-T
(c) SDS-TP (d) ADS-TP
(e) SDS-TE (f) ADS-TE
Fig. 4 Intrinsic drug orientation distributions for the various different
monolayer simulations. The monolayer system is labelled in each sub-
plot. For all plots, the colours red, green, blue and orange represent the
Headgroup, C1−4, C5−8 and C9−12 regions respectively.(Note: The errors
of these measurements are smaller than the size of the symbols used to
represent them.)
The TP molecules strongly populate the C1−4 region of the
monolayers, with a distribution centred at cos(θ) ∼ −0.13 which
corresponds to the TP molecules being oriented approximately
in the x-y plane within this part of the monolayer. This is shown
6 | 1–12Journal Name, [year], [vol.],
clearly by the prominent green curves in Figures 4c and 4d. When
TP is present in excess of the ratio of drug to surfactant found in
micelles, the C5−8 region becomes more populated and exhibits
peaks at cos(θ) = −0.9 corresponding to the TP molecules reori-
enting themselves such that the O1 atoms (see Figure 1) are near-
est the water in a similar way as for the T molecules.
The TE molecules show very similar distibutions of their orien-
tations as is observed with the TP molecules. Specifically, the TE
also occupy the C1−4 region and exhibit the same shift of popula-
tion to the C5−8 region when there is excess drug present within
the monolayers.
The rationale of these results comes from considering the com-
peting forces at play within these monolayers. Each of the
testosterone-based compounds have oxygen atoms O1 and O2 on
either end of the molecule which are capable of forming hydro-
gen bonds with the water in the solvent phase. Therefore, orien-
tations with the drug molecule being parallel to the x-y plane will
be preferable. This ensures that hydrogen bonds can be formed
between water molecules and these polar sites within the drug
molecule. For these hydrogen bonds to be formed, the drug
molecule must have some contact with water molecules which
explains why they sit in the C1−4 region which is close to the
headgroups and approximately the location of the interface with
the solvent phase within the monolayer, but also allows for the
drugs to form hydrophobic contacts. As more drug molecules are
packed into the monolayers within a fixed surface area, the pack-
ing of the monolayer chains and drugs causes the drug molecules
to reorient themselves such that they are approximately parallel
to the z-axis, and in doing so the centre of the molecule is moved
deeper into the monolayer. The mechanism behind this reorien-
tation is two-fold. First, the steric interactions become significant
as packing increases. Second, by reorienting the drug in this man-
ner interactions can be formed between the water molecules and
one end of the drug molecule which most strongly prefers interac-
tions with water. For all of the testosterone-based drug molecules,
there is a preference for the drug molecules to orient such that
the O1 atoms interact with the water in the solvent phase. For the
testosterone drugs, there is a smaller but significant population
of drug molecules which orient such that O2 interacts with the
water, but there is no such population for the TE or TP molecules
which have hydrophobic hydrocarbon chains attached to the O2
atoms that would cause this end of the molecule to be decidedly
less favourable to be in contact with water.
3.3 Monolayer structure
As the testosterone-based compounds are found to reside in the
region of the monolayer where the hydrocarbon tail joins the
DS− headgroup, it is predictable that the addition of testosterone-
based compounds has an appreciable effect on the structural
properties of surfactant monolayers. By developing a detailed un-
derstanding of this, the rationale behind enhancing the solubility
of poorly soluble drug compounds within surfactant aggregates
can be improved for formulations in the future. A summary of
the structural properties of the SDS and ADS monolayers can be
found in Tables 1 and 2, respectively. Additionally, the surfactant
Table 1 Structural properties of SDS monolayers containing T, TP and
TE.
System dtail dhead Roughness nH2O
(Å) (Å) (Å) (#/Å−2)
SDS-T-1 7.8 ± 0.2 2.2 ± 0.04 2.7 ± 0.2 0.16
SDS-T-17 9.0 ± 0.2 2.2 ± 0.04 2.6 ± 0.2 0.13
SDS-T-34 9.9 ± 0.2 2.2 ± 0.04 2.3 ± 0.2 0.11
SDS-TP-1 7.9 ± 0.2 2.2 ± 0.03 2.7 ± 0.2 0.15
SDS-TP-17 9.0 ± 0.2 2.2 ± 0.03 2.4 ± 0.2 0.12
SDS-TP-34 10.1 ± 0.2 2.2 ± 0.03 2.5 ± 0.2 0.10
SDS-TE-1 7.8 ± 0.3 2.2 ± 0.03 2.6 ± 0.2 0.15
SDS-TE-17 9.2 ± 0.2 2.2 ± 0.03 2.4 ± 0.2 0.11
SDS-TE-34 10.4 ± 0.2 2.2 ± 0.03 2.5 ± 0.2 0.10
Table 2 Structural properties of ADS monolayers containing T, TP and
TE.
System dtail dhead Roughness nH2O
(Å) (Å) (Å) (#/Å−2)
ADS-T-1 7.9 ± 0.2 2.2 ± 0.03 2.5 ± 0.2 0.10
ADS-T-8 8.3 ± 0.2 2.2 ± 0.03 2.5 ± 0.2 0.09
ADS-T-16 8.9 ± 0.2 2.2 ± 0.03 2.4 ± 0.2 0.08
ADS-TP-1 7.9 ± 0.2 2.2 ± 0.03 2.6 ± 0.2 0.10
ADS-TP-14 8.7 ± 0.2 2.2 ± 0.03 2.3 ± 0.2 0.07
ADS-TP-28 9.7 ± 0.2 2.2 ± 0.03 2.3 ± 0.2 0.05
ADS-TE-1 7.9 ± 0.2 2.2 ± 0.03 2.5 ± 0.2 0.10
ADS-TE-22 9.6 ± 0.2 2.2 ± 0.03 2.3 ± 0.2 0.06
ADS-TE-44 11.2 ± 0.2 2.2 ± 0.03 2.4 ± 0.2 0.04
chain tilt angle θt and the headgroup tilt angle θh were calculated
for all monolayer systems and their probability distributions are
shown in Figure 5, and the mean values of these angles have been
reported in Tables 3 & 4.
The thickness of the monolayer headgroup region, dhead is equal
to 2.2 Å for all of the systems. Meanwhile, there is a small shift
in the distributions of the head group tilt angle θt toward smaller
angles with increasing amounts of drug molecules within a mono-
layer, but the net effect on the mean value of this angle is gener-
ally insignificant. The distributions of θt also become more nar-
row with increasing amounts of drug. This indicates that as the
effective area per molecule in the monolayer reduces so do the
fluctuations in the conformations that the headgroup takes. Nei-
ther changing the counterion species, nor the presence of the dif-
ferent testosterone-based compounds, has any significant effect
on the conformation of the headgroups, which is consistent with
the results presented previously showing the drugs do not interact
strongly with the headgroup regions.
The addition of drug molecules results in a significant effect
on the structure of the hydrocarbon tails of the DS− surfactants.
From Tables 1 & 2, it is clear that there is a consistent trend of
increasing hydrocarbon tail thickness with increasing amounts of
drug molecules present in the monolayers. Additionally, Fig. 5
shows that the distributions of the tail tilt angle θt shift towards
smaller angles as the amount of drug molecules interacting with
the monolayer is increased. This trend is also confirmed by the
monotonically decreasing mean values of these distributions with
the addition of more drug molecules as shown in Tables 3 &
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4. Since the monolayers are always held at a constant surface
area, the area per surfactant molecule is reduced as more drug
molecules are added to the monolayer. Therefore the surfactant
tails are restricted to more rigid configurations which results in
an increase of the effective tail length.
Table 3 Average head group (θh) and tail (θt) tilt angles of SDS monolay-
ers containing T, TP and TE.
System θh (◦) θt (◦)
SDS-T-1 44.8 ± 23.2 44.3 ± 20.8
SDS-T-17 41.8 ± 22.1 37.1 ± 19.4
SDS-T-34 38.4 ± 20.8 30.4 ± 16.5
SDS-TP-1 44.8 ± 23.1 39.5 ± 18.8
SDS-TP-17 41.8 ± 21.7 33.2 ± 16.3
SDS-TP-34 38.0 ± 20.4 26.4 ± 14.5
SDS-TE-1 44.8 ± 23.1 43.9 ± 20.8
SDS-TE-17 41.0 ± 21.3 35.1 ± 17.5
SDS-TE-34 36.6 ± 19.8 27.0 ± 14.7
Table 4 Average head group (θh) and tail (θt) tilt angles of ADS monolay-
ers containing T, TP and TE.
System θh (◦) θt (◦)
ADS-T-1 44.7 ± 23.1 44.1 ± 20.7
ADS-T-8 43.3 ± 22.6 41.0 ± 20.2
ADS-T-16 42.1 ± 22.2 37.6 ± 19.2
ADS-TP-1 44.4 ± 23.0 43.7 ± 20.8
ADS-TP-14 42.4 ± 22.0 38.3 ± 18.7
ADS-TP-28 39.1 ± 20.6 31.6 ± 16.1
ADS-TE-1 44.7 ± 23.2 43.9 ± 20.8
ADS-TE-22 39.6 ± 20.7 32.6 ± 16.4
ADS-TE-44 34.2 ± 19.1 23.3 ± 13.4
The roughness was also quantified for all systems by calculat-
ing RMSD values, which generally yielded values in the range of
2 Å to 3 Å (see Tables 1 & 2). This shows that the addition of
testosterone-based compounds to the monolayers does not signif-
icantly compromise structural stability. Therefore the stability of
any ADS or SDS monolayer should not be affected by the encap-
sulation of these testosterone-based compounds.
We have also calculated the surface tension for each simulated
system, and the results are shown in the SI. The first thing to no-
tice is that the surface tension for the SDS and ADS monolayers
without any drug present are the same within the reported error
bars, so the counter ion has no significant effect on the surface
tension of these monolayers. Additionally, the results show that
the surface tension of the monolayers are unaffected by the pres-
ence of the testosterone (TO) in either monolayer. In the SDS-TE
and SDS-TP systems, we observe that when the ratio of drug to
surfactant is less than or equal to that found in micelles experi-
mentally, the presence of the drug has little effect on the surface
tension of the monolayers. However when TE and TP are present
at drug to surfactant ratios that are twice the ratio found in mi-
celles, we observe a significant decrease in surface tension for
the SDS monolayers. This observation is in agreement with our
recent experiments of the same systems over a number of concen-
trations of drugs in which we observed that there is a decrease in
the surface tension for SDS monolayers with an area per molecule
of ∼ 48 Å2 without drug (∼ 38 mN/m) and the same SDS mono-
layers with enough TE to saturate the monolayer (∼ 29 mN/m)48.
In the ADS monolayers, TP has no significant effect on the mea-
sured surface tension of any of the systems we studied. Whereas,
TE decreases the surface tension of the ADS monolayer when it
is present at a twice the drug to surfactant ratio found in mi-
celles. Therefore, in all of the systems in which we observed drug
molecules accumulating in the hydrocarbon tail regions of the
surfactant monolayers, which would be indicative of the surface
being saturated, we also observe that the presence of the drugs
cause a decrease in the surface tension of the monolayer.
(a) SDS-T (b) ADS-T
(c) SDS-TP (d) ADS-TP
(e) SDS-TE (f) ADS-TE
Fig. 5 Plots showing probability distributions of surfactant chain tilt, θt,
and headgroup tilt, θh, angles for all monolayer simulations. The plots
correspond to the various different monolayer simulations reported, as
described by the legends. (Note: The errors of these measurements are
smaller than the size of the symbols used to represent them.)
3.4 Effect of testosterone-based compounds on interactions
with the solvent phase
While the drug molecules do not appear to interact with the
surfactant head groups, the effect of the presence of the drug
molecules on the interactions of the DS− headgroups with wa-
ter and the counter ions has been investigated to see if there is
any significant change. The distributions of the hydration num-
ber around the surfactant head groups have been determined and
are presented in the SI. The distributions of the hydration num-
ber for each monolayer exhibit unimodal distributions centred
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around the mean value. The mean hydration number of each
monolayer simulation is shown in Tables 5 & 6. Comparing these
values reveals that the SDS monolayers are more hydrated than
ADS, for example in the simulations with a single drug molecule
present the hydration decreases from ∼ 12.4 H2O/molecule for
the SDS monolayers to ∼ 9.3 H2O/molecule for ADS monolay-
ers. The probability distributions do not change drastically when
the number of drug molecules per monolayer is varied, however
the mean hydration number does decrease slightly as the number
of drug molecules per monolayer is increased. Once again, the
counterion species seems to be the dominant factor in determin-
ing hydration.
Also, the distribution of the number of cations bound to the
DS− headgroup has been used to investigate any effect that the
presence of the drug molecules may have on interactions with the
ions. The average number of ions bound to the DS− headgroup
in each system is reported in Tables 5 & 6, and these values show
that there are more NH3+ ions bound per headgroup than Na+
ions, which is consistent with the findings in our previous study of
the interaction of different ions with the DS− headgroup26. While
the value of the average number of ions bound to the headgroup
increases with an increase in the number of drug molecules in the
monolayer, the change is not significant. Therefore it seems that
the presence of drugs has very little effect on the properties of the
interfaces between the monolayers and the solvent phase.
Table 5 Average number of first neighbour water molecules and Na+ ions
around the S atom in the SDS headgroup for the monolayers containing
T, TP and TE.
System nhgH2O n
hg
Na+
SDS-T-1 12.4 ± 2.2 0.90 ± 0.84
SDS-T-17 12.0 ± 2.3 0.95 ± 0.87
SDS-T-34 11.7 ± 2.3 0.99 ± 0.88
SDS-TP-1 12.4 ± 2.2 0.92 ± 0.86
SDS-TP-17 11.9 ± 2.3 0.95 ± 0.86
SDS-TP-34 11.4 ± 2.4 0.99 ± 0.86
SDS-TE-1 12.4 ± 2.2 0.94 ± 0.85
SDS-TE-17 11.8 ± 2.3 0.97 ± 0.85
SDS-TE-34 11.4 ± 2.4 1.01 ± 0.88
Table 6 Average number of first neighbour water molecules and NH3+
ions around the S atom in the ADS headgroup for the monolayers con-
taining T, TP and TE.
System nhgH2O n
hg
NH+3
ADS-T-1 9.3 ± 2.2 1.38 ± 0.96
ADS-T-8 9.2 ± 2.2 1.39 ± 0.96
ADS-T-16 9.1 ± 2.3 1.39 ± 0.96
ADS-TP-1 9.3 ± 2.2 1.38 ± 0.96
ADS-TP-14 9.1 ± 2.2 1.39 ± 0.94
ADS-TP-28 8.7 ± 2.3 1.44 ± 0.95
ADS-TE-1 9.4 ± 2.2 1.38 ± 0.96
ADS-TE-22 8.8 ± 2.3 1.43 ± 0.95
ADS-TE-44 8.3 ± 2.4 1.50 ± 0.96
3.5 Hydration of testosterone-based compounds
While the drug molecules have been observed to change their ori-
entation within the monolayers as more drugs are present, there
is most probably an effect on the interaction of the drug molecules
with water molecules and the ions in solution. Therefore, once
again, the number of nearest neighbour water molecules and ions
(Na+ in the SDS systems and NH+3 in the ADS systems) have been
determined around each oxygen in the different testosterone-
based compounds, and then the probability distribution of having
a certain number of water molecules and ions around each oxy-
gen was determined. These probability distributions, which are
displayed as histograms and are shown in the SI, exhibit unimodal
distributions in each case.
Table 7 shows the average number of nearest neighbour water
molecules around each of the oxygen atoms in the testosterone-
based compounds in both the SDS and ADS monolayers. From
these values, it is clear that there is a general trend in which the
testosterone-based compounds in the ADS monolayers are more
dehydrated than when they are in SDS monolayers. While the
drugs do not interact with the headgroups of the monolayers,
they do interact with the ions in solution, and from the distri-
butions shown in the SI, it is clear that the NH+3 ions in the ADS
systems interact more with the oxygens in the testosterone-based
compounds than the Na+ ions in the SDS systems do. As was
shown with their interactions with the DS− headgroups in a previ-
ous publication26, the NH+3 ions are able to form hydrogen bonds
with the oxygens (in particular O1 and O3, as shown in Fig. 1)
and therefore more directly compete with water for interactions
with these atoms, which the Na+ ions do not.
The trends of the hydration numbers for each of the different
testosterone-based compounds in the SDS monolayers and in the
ADS monolayers are similar. For example, in the case of testos-
terone (T) in both the monolayers, the average hydration num-
bers are not significantly affected by increasing the number of
drugs in the monolayers. In all systems the hydration of both
the O1 and O2 atoms is approximately the same. When there is
a single testosterone molecule in the monolayers, this is due to
them most probably being oriented parallel to the interface with
the water (as shown in Figs. 4a & 4b), so that both oxygens can
interact with interfacial water molecules. The orientational pref-
erences of the drugs in the two monolayers are reflected in the
number of first neighbour water molecules around the O1 and
O2 atoms in the testosterone molecules. In the ADS monolayers,
the number of water molecules around the two oxygen atoms re-
mains more or less constant with the number of drug molecules
within the monolayers as they always prefer to be parallel to the
interface with the water. While for the drugs in SDS, the number
of first neighbour water molecules around O1 becomes increas-
ingly larger than that found around the O2 atoms as the number
of drug molecules increases and the drug molecules increasingly
prefer to orient such that the O1 atoms are near the water and the
O2 atoms are close to the vacuum region.
In the ADS monolayers, the hydration of the testosterone propi-
onate (TP) molecules does not show any significant change with
an increasing number of drugs present in the monolayer. This
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hydration behaviour is consistent with the fact that the preferred
orientation of the TP molecules in the ADS monolayers is such
that the molecule is parallel to the water interface, independent
of the number of drugs present (see Fig. 4d). Whereas, in the SDS
monolayers, the hydration of the O1 atom remains approximately
constant independent of the number of drug molecules present.
However, the O2 and O3 atoms dehydrate by approximately the
same amount with increasing amounts of drug in the monolayer
(∼ 10% for 17 TP molecules and∼ 40% for 34 TP molecules). This
dehydration is a result of the TP molecules reorienting such that
the end of the molecule containing the O2 and O3 atoms and the
hydrocarbon chain moves into the vacuum region of the system
with increasing number of drugs present (see Fig. 4c).
The hydration of the O1, O2 and O3 atoms in the testosterone
enanthate (TE) molecules follow the same trends with increasing
number of drug molecules in both of the monolayers. The number
of first neighbour water molecules around the O1 atoms slightly
increases as the number of drug molecules increases. Meanwhile
the number of hydrating of water molecules around both the
O2 and O3 atoms decreases significantly (> 50% for the systems
which have a larger drug to surfactant ratio than found in a mi-
celle) as the number of drug molecules increases. This trend is
once again consistent and seemingly a result of the fact that the
TE molecules reorient from being parallel to the water interface
to being perpendicular to the water interface with the O1 atom
nearest the water as the number of drug molecules increase (see
Figs. 4e & 4f).
Table 7 Average number of first neighbour watr molecules around oxygen
atoms of the testosterone-based compounds (O1, O2, & O3 as seen in
Fig. 1) in the various SDS and ADS monolayer systems.
System nO1H2O n
O2
H2O n
O3
H2O
SDS-T-1 2.2±0.8 2.1±0.9 —
SDS-T-17 2.0±1.4 1.9±1.7 —
SDS-T-34 1.9±1.5 1.5±1.7 —
SDS-TP-1 2.6±0.7 0.8±0.4 4.0±1.0
SDS-TP-17 2.5±1.3 0.7±0.7 3.7±1.9
SDS-TP-34 2.5±1.6 0.5±0.6 2.3±2.3
SDS-TE-1 2.6±0.7 0.8±0.4 4.1±1.0
SDS-TE-17 2.6±1.3 0.7±0.7 3.5±1.8
SDS-TE-34 2.8±1.6 0.4±0.6 2.0±2.0
ADS-T-1 1.3±0.5 1.3±0.7 —
ADS-T-8 1.2±0.9 1.3±1.1 —
ADS-T-16 1.1±0.9 1.3±1.2 —
ADS-TP-1 1.3±0.4 0.8±0.4 1.6±0.7
ADS-TP-14 1.2±0.8 0.8±0.8 1.6±1.3
ADS-TP-28 1.1±0.9 0.7±0.7 1.3±1.3
ADS-TE-1 1.3±0.5 0.7±0.4 1.6±0.8
ADS-TE-22 1.4±1.0 0.7±0.7 1.5±1.3
ADS-TE-44 1.7±1.2 0.3±0.6 0.6±1.0
4 Discussion
A series of MD simulations investigating the interactions between
SDS and ADS monolayers and three different testosterone-based
compounds (testosterone (T), testosterone propionate (TP) and
testosterone enanthate (TE)) were conducted to show how the
structural and interfacial properties of the monolayer are affected
by changing the number of drug molecules present per mono-
layer, and the chemical nature of the surfactant counterions and
the testosterone-based compounds.
The results show that the encapsulation and resultant struc-
ture of the molecules within the monolayers are dependent upon
both the chemistry of the drugs and the counterion used to neu-
tralise the DS− monolayers. The counterion affects the proper-
ties related to hydration of the monolayers and the drugs. The
chemistry of the drug plays a role in the preferred orientation of
the drug molecule within the monolayers, particularly once the
number of drugs within the monolayer is above the saturation
level. Finally, the number of drugs within the monolayers affect
the structure of the monolayer, the position and orientation of the
drug molecules within the monolayer and the amount of water
found within the monolayer.
The interfacial water structure in the SDS monolayer systems
includes a layer of water molecules which are seemingly well
ordered, whereas the water near the ADS monolayers show no
such ordering. When investigating the hydration of the surfac-
tant headgroups, the SDS monolayers were found to be signif-
icantly more hydrated than the ADS monolayers, which is con-
sistent with previous findings that the NH+3 ions compete with
water when binding to the DS− headgroups, and therefore re-
duce the number of nearest neighbour water molecules26. How-
ever, increasing the number of drug molecules in the monolayer
only minimally affects the surfactant headgroup hydration, which
decreased slightly as the number of drug molecules present per
monolayer increased.
In addition to reducing the hydration of the headgroups of the
DS− molecules, the NH+3 ions also reduce the amount of water
that penetrates the monolayers when compared to that found
when Na+ ions are present. The amount of water that pene-
trates the ADS monolayers is approximately 50% smaller than
that which penetrates the SDS monolayers. Additionally, in each
monolayer, the amount of water that penetrates the monolayer
reduces as the number of drug molecules that are present within
the monolayers, as there is more steric hinderance to the diffusion
of water.
The monolayer structural properties revealed that the mono-
layer headgroup thickness, dhead, remains constant in every mono-
layer system reported. However, the thickness of the hydrocarbon
tail region, dtail, increases as more drug molecules are added to
the monolayer due to packing constraints. Distributions of the
surfactant chain tilt, θt , and headgroup tilt angles, θh, shift to-
wards smaller values as more drug molecules are added to the
monolayers, an effect which is coupled with the observation of
increased monolayer thickness. These trends are consistently ob-
served independent of the chemistry of the testosterone-based
compounds.
The location and orientation of the testosterone-based
molecules within the different monolyers vary with the chem-
istry of the drug molecules and the number of each molecule
in the monolayer; however there are some general trends that
are observed in the various systems. When the number of the
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drug molecules is at or less than the amount required to saturate
the monolayer, the drug molecules prefer to reside within the
monolayer in the C1−4 region with an orientation such that the
molecule is parallel to the water interface. When the drug to sur-
factant ratio is greater than or equal to that found in micelles, the
centre of the drug molecules are found to be located deeper into
the hydrophobic chains of the surfactants and then they orient
themselves such that they are nearly perpendicular to the inter-
face with the water interface such that the O1 atoms in the drug
molecules are closest to the water. In doing so, the O1 oxygen
can hydrogen bond with the water molecules and the hydrocar-
bon tail is able to interact with the hydrocarbon tails of the surfac-
tant when the packing increases within the monolayer. The only
systems that differs from these trends are the ones with testos-
terone (T) molecules. In the systems with T molecules, there is a
large population which orient with the O1 atoms nearest the wa-
ter interface, and there is also a population, which is smaller in
number, of drug molecules that oriented with the O2 atom closest
to the water.
The hydration of the oxygens within the drug molecules is af-
fected by the rotation of the molecules within the monolayers.
Therefore while there is a general reduction in the hydration of
the oxygens in the drug molecules as the number of drugs in a
monolayer increases, the degree to which the hydration is de-
creased around the O2 (and O3) atom(s) of the drug molecule
increases with increasing hydrocarbon chain length (T > TP >
TE). Also the drug molecules in the ADS monolayers generally
show that they have roughly half of the number of hydrating
water molecules around their oxygens as compared to the drug
molecules in the SDS monolayers. This results from the fact that
there is approximately half as much water that penetrates into the
ADS monolayers as compared to the SDS monolayers.
To conclude, we have provided direct evidence of how subtle
changes in the chemistry of drug molecules and the surfactant
molecules used to encapsulate them can have a significant ef-
fect on the structure of the resulting aggregate and therefore the
amount of drug that can be encapsulated. One example of this
phenomena in practice is the recent experimental work showing
that ADS micelles have a poorer solubilisation capacity for encap-
sulating testosterone derivatives than SDS micelles despite being
having a larger aggregation number and lower hydration49. Our
results suggest that this is due to the testosterone-based com-
pounds being significantly dehydrated within the aggregates of
ADS as compared to when they are encapsulated within aggre-
gates of SDS.
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